SMART Medical Systems Ltd., a developer and manufacturer of innovative endoscopy products, today reported positive data from a multicenter clinical study (NCT 04708951) comparing the adenoma detection rate (ADR) of its FDA-cleared G-EYE® balloon technology against ENDOCUFF VISION® (ECV) technology in patients undergoing screening or surveillance colonoscopy. Results from this randomized trial, the first head-to-head comparison of these two colonoscopy mechanical enhancement devices, showed that the ADR, particularly for advanced and large adenomas, was higher for the G-EYE® balloon than for the ECV attachment. Seth Gross, MD, Professor, Department of Medicine at NYU Grossman School of Medicine, Clinical Chief, Division of Gastroenterology and Hepatology at NYU Langone Health, and co-author on the abstract, presented the data in an oral session at ACG 2021, which is taking place October 22-27 in Las Vegas (ACG 2021, Presidential Plenary Session 1, Abstract #S233).
Trending
- Congratulations Dr. Kim on new AAAHC leadership position (AGA)
- When RVUs Go Wrong: Red Flags for Physicians (Medscape)
- GI Side Effects of Immune Checkpoint Inhibitors Linked to Colon Adenoma Risk (GI & Hepatology News)
- Would You Track Your Stools Like You Track Your Steps? (Bloomberg)
- Good news, bad news for gastroenterology (Becker’s GI & Endoscopy)
- Addressing Colonoscopy Burden due to Artificial Intelligence Devices for Polyp Detection (Gastro Journal)
- Gastro Center of Maryland Expands to Bethesda and Silver Spring, Broadening Access to GI Care in the DMV (USA Today)
- To Improve CRC Screening in Patients Aged 45-49, Just Send Them a FIT Kit (GI & Endoscopy News)
